VOR Stock Forecast: Vor Biopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$19
+3.46% on the day

The 10 Wall Street analysts covering Vor Biopharma, Inc. hold a median 12-month price target of $40 — +108.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 23 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
23/ 100
Median analyst target
$40
Analysts covering
10
Revenue$0.0
Operating income−$47.9M
Net income−$62.8M
Free cash flow−$25.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
+0.7%
YTD
+46.5%
1Y
+179.3%
From 52W high
−23.7%
From 52W low
+179.3%
$7
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Vor Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
23/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
84
Value
69
Momentum
47
Quality
34
Issuance
23
Volatility
22
Revisions
21
Accruals
14

Growth (84): Sales and profits are climbing, and climbing faster than before.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26VORHigh $50Median $40Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9
Buy
1
Hold
0
Sell
$27
Low
$40
Median
$50
High

The green dot is the last close — the median target sits +108.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Oct 2026William BlairInitiatesOutperform—
12 Aug 2026WedbushMaintainsNeutral$18 → $27
18 May 2026HC Wainwright & Co.ReiteratesBuy$31
14 May 2026WedbushMaintainsNeutral$15 → $18
15 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushMaintainsNeutral—
30 Mar 2026JefferiesInitiatesBuy—
19 Mar 2026Wells FargoInitiatesOverweight—
9 Jan 2026CitigroupInitiatesBuy—
19 Dec 2025JP MorganMaintainsOverweight—
17 Dec 2025TD CowenInitiatesBuy—
9 Dec 2025JP MorganInitiatesOverweight—
25 Nov 2025WedbushAssumesNeutral$9.00
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
29 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025BairdUpgradeOutperform—
14 Aug 2025HC Wainwright & Co.ReiteratesBuy—
30 June 2025HC Wainwright & Co.UpgradeBuy—
27 June 2025BairdMaintainsNeutral—
26 June 2025WedbushReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VOR.

Market Radar

This page is one stock. Monday covers all of them.

VOR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VOR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Vor Biopharma, Inc. returned +179.3% against +6.9% for the S&P 500, dividends included.

VOR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26VORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−27.5%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vor Biopharma, Inc. has a market value of $1.2B and an enterprise value of $700.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: $627.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$140.8M.

  • Shares outstanding: 54.5M.

  • Trailing P/E: 0.1×.

  • Vor Biopharma, Inc. employs 76 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

VOR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VORVor Biopharma, Inc.$1.2B23
DRTSAlpha Tau Medical Ltd.$1.1B15
MNKDMannKind Corp.$1.2B41
TSHATaysha Gene Therapies, Inc.$1.2B56
KARDKardigan, Inc.$1.1B3
GHRSGH Research Plc$1.2B62
MLYSMineralys Therapeutics, Inc.$1.2B13

Take a look at VOR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Vor Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VOR

What is the VOR stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Vor Biopharma, Inc. have a median 12-month price target of $40, with estimates ranging from $27 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VOR stock a buy right now?

Of the 10 analysts covering Vor Biopharma, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vor Biopharma, Inc. 23 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VOR?

As at 21 Nov 2026, Vor Biopharma, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).

Will VOR stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +108.8% from the last close, and Ticker Nerd's factor model ranks Vor Biopharma, Inc. 23 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VOR stock forecast for 2030?

No analyst covering Vor Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $50 over the next 12 months.

How has VOR stock performed over the past year?

Vor Biopharma, Inc. returned +179.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vor Biopharma, Inc. do?

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions.

Company

About Vor Biopharma, Inc.

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions. The company’s current development and commercialization efforts center on autoimmune indications such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, and IgA nephropathy. Vor Biopharma works on advancing this therapy through clinical development and broader market access, positioning its platform within the specialized immunology and biopharmaceutical segments. Headquartered in Cambridge, Massachusetts, Vor Biopharma plays a role in the market by addressing serious chronic diseases with targeted biologic treatment approaches.

CEO Dr. Jean-Paul Kress M.D. · 76 employees · United States · https://www.vorbio.com